Incyte and Edison Scientific have entered a strategic collaboration to integrate Edison’s AI scientist platform, Kosmos, into Incyte’s drug discovery and development workflows.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Incyte and Edison Scientific have entered a strategic collaboration to deploy Edison’s AI scientist platform, Kosmos, across Incyte’s drug discovery and development operations. The partnership is designed to integrate AI-driven learning systems into research workflows, enabling continuous analysis of translational and clinical data, real-time evidence synthesis, and predictive modeling of therapeutic performance.
The platform is also intended to support hypothesis generation and evaluation, while assisting research and development decision-making across multiple stages of drug development.
The initial phase of the collaboration will focus on target discovery, target validation, and translational biology. Under the agreement, Edison’s AI tools will be embedded into Incyte’s existing research infrastructure to support the analysis of experimental, clinical, and biomarker datasets. The companies said the collaboration could later expand across Incyte’s broader research and development organization.
According to the companies, the partnership aims to create a data-driven learning system in which experimental and clinical findings continuously improve AI models over time. The approach is intended to support more informed scientific decision-making and improve long-term pipeline productivity.
Pablo J. Cagnoni, M.D., President and Global Head of Research and Development at Incyte said the collaboration is intended to help Incyte use its internal data more effectively to improve experimental design and strengthen the consistency and quality of development decisions across programs.
Patrick Mayes, Ph.D., Executive Vice President and Chief Scientific Officer at Incyte said integrating systems that learn from experimental and clinical datasets could improve interpretation of research findings and create a feedback process that enhances future development programs.
Sam Rodriques, Ph.D., Chief Executive Officer of Edison Scientific said the collaboration is focused on building AI systems that continuously learn from accumulated research and clinical data, with the goal of improving underlying predictive models and supporting long-term competitive advantages in drug development.
Reference
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.
